JNJ

229.64

+0.81%↑

UNH

369.73

+0.08%↑

TMO

476.34

+1.91%↑

ISRG

454.78

+0.68%↑

ABT

90.61

-1.86%↓

JNJ

229.64

+0.81%↑

UNH

369.73

+0.08%↑

TMO

476.34

+1.91%↑

ISRG

454.78

+0.68%↑

ABT

90.61

-1.86%↓

JNJ

229.64

+0.81%↑

UNH

369.73

+0.08%↑

TMO

476.34

+1.91%↑

ISRG

454.78

+0.68%↑

ABT

90.61

-1.86%↓

JNJ

229.64

+0.81%↑

UNH

369.73

+0.08%↑

TMO

476.34

+1.91%↑

ISRG

454.78

+0.68%↑

ABT

90.61

-1.86%↓

JNJ

229.64

+0.81%↑

UNH

369.73

+0.08%↑

TMO

476.34

+1.91%↑

ISRG

454.78

+0.68%↑

ABT

90.61

-1.86%↓

Search

Cencora Inc

Abrir

SetorSaúde

305.12 -2.14

Visão Geral

Variação de preço das ações

24h

Atual

Mín

298.7

Máximo

312.67

Indicadores-chave

By Trading Economics

Rendimento

906M

566M

Vendas

2.2B

86B

P/E

Médio do Setor

37.19

67.147

EPS

4.08

Rendimento de Dividendos

0.73

Margem de lucro

0.659

Funcionários

47,000

EBITDA

858M

1B

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+29.04% upside

Dividendos

By Dow Jones

Rendimento de Dividendos

Médio do Setor

0.73%

2.36%

Próximos Ganhos

6 de mai. de 2026

Próxima data de dividendos

1 de jun. de 2026

Próxima data de ex-dividendo

15 de mai. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-10B

60B

Abertura anterior

307.26

Fecho anterior

305.12

Sentimento de Notícias

By Acuity

7%

93%

6 / 348 Ranking em Healthcare

Cencora Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

29 de abr. de 2026, 23:53 UTC

Ganhos

Naver Posts Weaker First-Quarter Earnings

29 de abr. de 2026, 23:41 UTC

Ações em Alta

Stocks to Watch: Meta Platforms, Alphabet, Qualcomm, Amazon.com

29 de abr. de 2026, 23:55 UTC

Ganhos

Samsung Electronics 1Q Net Profit Beat FactSet-Compiled Consensus

29 de abr. de 2026, 23:54 UTC

Ganhos

Samsung Electronics 1Q Net KRW47.225T Vs. Net KRW8.223T >005930.SE

29 de abr. de 2026, 23:52 UTC

Ganhos

Samsung Electronics 1Q Oper Pft KRW57.233T Vs. Pft KRW6.685T >005930.SE

29 de abr. de 2026, 23:51 UTC

Ganhos

Samsung Electronics 1Q Rev KRW133.873T Vs. KRW79.141T >005930.SE

29 de abr. de 2026, 23:51 UTC

Conversa de Mercado

Nikkei May Fall Amid Uncertainty Over Mideast Conflict -- Market Talk

29 de abr. de 2026, 23:34 UTC

Conversa de Mercado

Gold Edges Higher on Likely Technical Recovery -- Market Talk

29 de abr. de 2026, 23:24 UTC

Ganhos

CSC Financial 1Q Results Supported By Higher Income From Fees, Commission>6066.HK

29 de abr. de 2026, 23:24 UTC

Ganhos

CSC Financial Gains From Changes in Fair Value on Financial Assets Also Aided Results>6066.HK

29 de abr. de 2026, 23:24 UTC

Ganhos

CSC Financial 1Q Net CNY3.67B Vs. Net CNY1.84B >6066.HK

29 de abr. de 2026, 23:24 UTC

Ganhos

CSC Financial 1Q Rev CNY7.70B Vs. CNY4.74B >6066.HK

29 de abr. de 2026, 23:22 UTC

Ganhos

China Longyuan 1Q Net CNY1.70B, Down 14%

29 de abr. de 2026, 23:22 UTC

Ganhos

China Longyuan: Power Generation Down 2.9% as of End-March

29 de abr. de 2026, 23:20 UTC

Ganhos

China Longyuan: 1Q Rev From Wind Power Fell, Rev From Solar Power Rose

29 de abr. de 2026, 23:20 UTC

Ganhos

China Longyuan 1Q Rev CNY7.87B, Down 3.6%

29 de abr. de 2026, 23:19 UTC

Ganhos

China Vanke 1Q Loss CNY5.95B Vs. Loss CNY6.25B >000002.SZ

29 de abr. de 2026, 23:19 UTC

Ganhos

China Vanke: Weak China Real Estate Market Continue to Weigh on Results>000002.SZ

29 de abr. de 2026, 23:19 UTC

Ganhos

China Vanke 1Q Rev CNY28.93B Vs. CNY37.99B >000002.SZ

29 de abr. de 2026, 23:19 UTC

Ganhos

China Vanke 1Q Loss Narrows>000002.SZ

29 de abr. de 2026, 23:18 UTC

Ganhos

Naver1Q Net Profit Missed FactSet-Compiled Consensus

29 de abr. de 2026, 23:17 UTC

Ganhos

Naver 1Q Net KRW291.00B Vs. Net KRW423.70B >035420.SE

29 de abr. de 2026, 23:15 UTC

Ganhos

Naver 1Q Oper Pft KRW541.80B Vs. Pft KRW505.30B >035420.SE

29 de abr. de 2026, 23:15 UTC

Ganhos

Naver 1Q Rev KRW3.241T Vs. KRW2.787T >035420.SE

29 de abr. de 2026, 23:13 UTC

Ganhos

CICC: Gains From Investments in Financial Instruments Also Aided Results >3908.HK

29 de abr. de 2026, 23:12 UTC

Ganhos

CICC Results Supported by Increase in Fee, Commission Income >3908.HK

29 de abr. de 2026, 23:11 UTC

Ganhos

CICC 1Q Rev CNY8.83B Vs. CNY5.72B >3908.HK

29 de abr. de 2026, 23:11 UTC

Ganhos

CICC 1Q Net CNY3.58B Vs. Net CNY2.04B >3908.HK

29 de abr. de 2026, 23:04 UTC

Ganhos

Microsoft Reports Strong Cloud Growth, but Questions About AI Returns Persist -- WSJ

29 de abr. de 2026, 23:04 UTC

Ganhos

Meta Reports Big Revenue Jump and Projected Spending Increase -- 3rd Update

Comparação entre Pares

Variação de preço

Cencora Inc Previsão

Preço-alvo

By TipRanks

29.04% parte superior

Previsão para 12 meses

Média 401.86 USD  29.04%

Máximo 429 USD

Mínimo 360 USD

Com base em 8 analistas de Wall Street que oferecem metas de preço de 12 meses para Cencora Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

8 ratings

6

Comprar

2

Manter

0

Vender

Sentimento

By Acuity

6 / 348 Ranking em Saúde

Sentimento de Notícias

Evidência Muito Forte de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Cencora Inc

Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and other services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers. This segment also distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; and offers other services to physicians who specialize in various disease states, such as oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. Its International Healthcare Solutions segment provides international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals; and offers specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was founded in 1871 and is headquartered in Conshohocken, Pennsylvania.
help-icon Live chat